Avicanna (FRA:0NN) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0NN Avicanna Inc FRA:0NN
45 GF Score
Price €0.06
GF Value €0.16
! 3 Warning Signs
View Full Analysis

What is Avicanna Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:0NN
45GF Score
Avicanna Inc FRA:0NN
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avicanna (FRA:0NN) Overvalued in 2026?

Based on GuruFocus' analysis, Avicanna stock appears to be undervalued. The current stock price of €0.06 is trading 61.6% below its estimated GF Value™ of €0.16.

Key valuation signals for FRA:0NN:

  • Interest Received:
  • GF Value™: €0.16 vs. price of €0.06 (61.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the FRA:0NN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avicanna Business Description

Address 480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc. is a Canadian biopharmaceutical company focused on the development and commercialization of cannabinoid-based products for medical and pharmaceutical markets. Its operations span three segments: Canada, International, and Corporate. The company develops proprietary formulations and active pharmaceutical ingredients derived from cannabis, offering products that include medical cannabis oils, capsules, topicals, and derma-cosmetics, sold under brands such as Pura Earth, RHO Phyto, and Aureus. Avicanna also pursues pharmaceutical development through its pipeline of evidence-based cannabinoid formulations targeting conditions such as dermatology, pain, and epilepsy. It serves medical patients, healthcare practitioners, and pharmaceutical partners, with commercial activity concentrated in Canada and expanding international markets including Latin America and Europe. Revenue is generated primarily through product sales in Canada, alongside licensing, research, and partnership arrangements internationally. The company operates cultivation and extraction infrastructure in Colombia to support its supply chain.
45GF Score

Get the complete analysis for FRA:0NN

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.16
GF Value